| Literature DB >> 31052232 |
Megan M Marron1, Tamara B Harris2, Robert M Boudreau3, Clary B Clish4, Steven C Moore5, Rachel A Murphy6, Venkatesh L Murthy7, Jason L Sanders8, Ravi V Shah9, George C Tseng10,11, Stacy G Wendell12, Joseph M Zmuda13,14, Anne B Newman15,16.
Abstract
Black versus white older Americans are more likely to experience frailty, a condition associated with adverse health outcomes. To reduce racial disparities in health, a complete understanding of the pathophysiology of frailty is needed. Metabolomics may further our understanding by characterizing differences in the body during a vigorous versus frail state. We sought to identify metabolites and biological pathways associated with vigor to frailty among 287 black men ages 70-81 from the Health, Aging, and Body Composition study. Using liquid chromatography-mass spectrometry, 350 metabolites were measured in overnight-fasting plasma. The Scale of Aging Vigor in Epidemiology (SAVE) measured vigor to frailty based on weight change, strength, energy, gait speed, and physical activity. Thirty-seven metabolites correlated with SAVE scores (p < 0.05), while adjusting for age and site. Fourteen metabolites remained significant after multiple comparisons adjustment (false discovery rate < 0.30). Lower values of tryptophan, methionine, tyrosine, asparagine, C14:0 sphingomyelin, and 1-methylnicotinamide, and higher values of glucoronate, N-carbamoyl-beta-alanine, isocitrate, creatinine, C4-OH carnitine, cystathionine, hydroxyphenylacetate, and putrescine were associated with frailer SAVE scores. Pathway analyses identified nitrogen metabolism, aminoacyl-tRNA biosynthesis, and the citric acid cycle. Future studies need to confirm these SAVE-associated metabolites and pathways that may indicate novel mechanisms involved in the frailty syndrome.Entities:
Keywords: African Americans; frailty; healthy aging; metabolomics
Year: 2019 PMID: 31052232 PMCID: PMC6572139 DOI: 10.3390/metabo9050083
Source DB: PubMed Journal: Metabolites ISSN: 2218-1989
Characteristics of 287 black men from the Health, Aging, and Body Composition study by tertiles of scores on the Scale of Aging Vigor in Epidemiology (SAVE).
| Mean (Standard Deviation) or Frequency (Percent) | SAVE Tertiles | Overall | ||
|---|---|---|---|---|
| Vigorous (T1) | Average (T2) | Frail (T3) | ||
| SAVE scores | 2.4 (0.7) | 4.5 (0.5) | 7.0 (1.1) | - |
| Age | 74 (3) | 75 (3) | 75 (3) | 0.006, T1 < T2, T3 |
| Pittsburgh site | 34 (47%) | 56 (53%) | 63 (58%) | 0.33 |
| More than high school education | 28 (38%) | 24 (23%) | 28 (26%) | 0.06 |
| Current smoker at baseline | 9 (12%) | 22 (21%) | 21 (19%) | 0.31 |
| Body mass index (kg/m2) | 27 (4) | 27 (4) | 27 (5) | 0.82 |
| Dietary intake: | ||||
| Total calories (Kcal/day) | 2329 (1111) | 2199 (1022) | 2095 (1038) | 0.35 |
| Protein intake (g/day) | 81 (44) | 75 (37) | 73 (39) | 0.41 |
| Percent of daily calories from protein | 14 (3) | 14 (3) | 14 (3) | 0.82 |
| Daily protein intake per body weight (g/kg) | 1.0 (0.6) | 0.97 (0.5) | 0.94 (0.5) | 0.71 |
| Fat intake (g/day) | 92 (51) | 87 (49) | 81 (48) | 0.30 |
| Percent of daily calories from fat | 35 (6) | 35 (8) | 34 (8) | 0.57 |
| Body composition: | ||||
| Appendicular lean mass (kg/m2) | 8.4 (1) | 8.3 (1) | 8.3 (1) | 0.68 |
| Percent fat | 28 (5) | 28 (5) | 28 (6) | 0.92 |
| Inflammation markers: | ||||
| Interleukin-6 (pg/mL) | 4.2 (5.9) Median = 2.5 | 3.2 (2.2) Median = 2.4 | 4.2 (3.4) Median = 3.0 | 0.05 |
| C-reactive protein (ug/mL) | 5.4 (8.9) Median = 2.8 | 5.3 (9.7) Median = 2.1 | 8.4 (16) Median = 3.9 | 0.05 |
| Markers of kidney disease at baseline: | ||||
| Creatinine (mg/dL) | 1.2 (0.2) Median = 1.2 | 1.2 (0.3) Median = 1.2 | 1.3 (0.4) Median = 1.2 | 0.04 |
| Cystatin C (mg/L) | 1.0 (0.2) Median = 0.96 | 1.0 (0.3) Median = 1.0 | 1.1 (0.3) Median = 1.1 | 0.05 |
| Glomerular filtration rate | 77 (17) | 75 (19) | 70 (19) | 0.03, T1 > T3 |
| Prevalent disease at baseline: | ||||
| Cardiovascular disease | 11 (15%) | 36 (34%) | 39 (36%) | 0.006, T1 < T2, T3 |
| Hypertension | 34 (47%) | 65 (62%) | 67 (61%) | 0.08 |
| Diabetes | 8 (11%) | 18 (17%) | 37 (34%) | 0.0004, T1, T2 < T3 |
| Cancer | 10 (14%) | 11 (10%) | 11 (10%) | 0.72 |
| Peripheral artery disease | 2 (3%) | 7 (7%) | 9 (8%) | 0.32 |
| Osteoarthritis | 2 (3%) | 9 (9%) | 11 (10%) | 0.17 |
| Depression | 4 (5%) | 5 (5%) | 8 (7%) | 0.71 |
| Pulmonary disease | 7 (10%) | 8 (8%) | 21 (19%) | 0.02, T2<T3 |
| Kidney disease | 1 (1%) | 2 (2%) | 0 | 0.36 |
| Medication use: | ||||
| Total number of prescription medications | 2.2 (2) | 3.0 (3) | 4.0 (4) | 0.0003, T1,T2 < T3 |
| Antihypertensive medications | 35 (48%) | 64 (61%) | 74 (68%) | 0.03, T1 < T3 |
| Antilipemic medications | 14 (19%) | 11 (10%) | 17 (16%) | 0.25 |
| Medications for diabetes: | 5 (7%) | 17 (16%) | 36 (33%) | <0.0001, T1, T2 < T3 |
| Insulin | 0 | 2 (2%) | 10 (9%) | 0.004, T1, T2 < T3 |
| Oral hypoglycemic | 5 (7%) | 15 (14%) | 28 (26%) | 0.003, T1, T2 < T3 |
| Medications for prostate disease | 10 (14%) | 14 (13%) | 19 (17%) | 0.83, P = 0.66 |
| Medications for pulmonary diseases | 5 (7%) | 2 (2%) | 13 (12%) | 0.02, T2 < T3 |
| Spasmolytics (theophylline and others) | 0 | 1 (1%) | 5 (5%) | 0.09 |
| Anti-inflammatory | 24 (33%) | 43 (41%) | 52 (49%) | 0.09 |
Age and study site-adjusted correlation of 37 top metabolites with scores on the Scale of Aging Vigor in Epidemiology (SAVE) (p < 0.05) and attenuations after further adjustments among 287 black men from the Health, Aging, and Body Composition study.
| Log-Transformed and | Human Metabolome Database | Human Metabolome Database | Continuous SAVE Scores, | Continuous SAVE Scores, | ||
|---|---|---|---|---|---|---|
| Correlation, | False Discovery Rate | Correlation, | Percent | |||
| Glucuronate | HMDB00127 | Carbohydrates/carbohydrate conjugates | 0.21, | 0.08 | 0.12, | 49% |
| Tryptophan | HMDB00929 | Indolyl carboxylic acids/derivatives | −0.21, | 0.08 | −0.18, | 15% |
| Methionine | HMDB00696 | Amino acids/peptides/analogues | −0.19, | 0.15 | −0.13, | 16% |
| N-carbamoyl-beta-alanine | HMDB00026 | Ureas | 0.17, | 0.22 | 0.13, | 39% |
| Tyrosine | HMDB00158 | Amino acids/peptides/analogues | −0.17, | 0.22 | −0.16, | −5% |
| Isocitrate | HMDB00193 | Tricarboxylic acids and derivatives | 0.17, | 0.22 | 0.11, | 40% |
| Creatinine | HMDB00562 | Amino acids/peptides/analogues | 0.16, | 0.27 | 0.02, | 89% |
| C4-OH carnitine | HMDB13127 | Beta hydroxy acids/derivatives | 0.16, | 0.27 | 0.10, | 34% |
| C14:0 SM | HMDB12097 | Phosphosphingolipids | −0.15, | 0.27 | −0.14, | −6% |
| Cystathionine | HMDB00099 | Amino acids/peptides/analogues | 0.15, | 0.27 | 0.11, | 32% |
| Hydroxyphenylacetate | HMDB00020 | 1-hydroxy-2-unsubstituted benzenoids | 0.15, | 0.27 | −0.004, | 103% |
| Putrescine | HMDB01414 | Amines | 0.15, | 0.27 | 0.11, | 16% |
| 1-methylnicotinamide | HMDB00699 | Pyridinecarboxylic acids/derivatives | −0.15, | 0.27 | −0.18, | −25% |
| Asparagine | HMDB00168 | Amino acids/peptides/analogues | −0.15, | 0.27 | −0.12, | 13% |
| Leucine | HMDB00687 | Amino acids/peptides/analogues | −0.14, | 0.35 | −0.19, | −34% |
| 5-aminolevulinic acid | HMDB01149 | Amino acids/peptides/analogues | 0.14, | 0.36 | −0.02, | 113% |
| Inosine | HMDB00195 | Not available | 0.14, | 0.39 | 0.12, | 16% |
| Histidine | HMDB00177 | Amino acids/peptides/analogues | −0.13, | 0.39 | −0.12, | 4% |
| C34:3 PE plasmalogen | HMDB11343 | Glycerophosphoethanolamines | −0.13, | 0.39 | −0.08, | −15% |
| Symmetric dimethylarginine (SDMA) | HMDB03334 | Amino acids/peptides/analogues | 0.13, | 0.39 | 0.02, | 86% |
| C24:1 ceramide (d18:1) | HMDB04953 | Ceramides | 0.13, | 0.39 | 0.12, | −7% |
| C36:4 PE | HMDB08937 | Glycerophosphoethanolamines | 0.13, | 0.39 | 0.07, | 43% |
| Urate | HMDB00289 | Purines/purine derivatives | 0.13, | 0.39 | 0.11, | 21% |
| C18:2 CE | HMDB00610 | Steroid esters | −0.13, | 0.39 | −0.09, | 22% |
| Trimethylamine-N-oxide | HMDB00925 | Aminoxides | 0.13, | 0.39 | 0.02, | 80% |
| 2-hydroxyglutarate | HMDB00694 | Short-chain hydroxy acids/derivatives | 0.13, | 0.39 | 0.07, | 49% |
| C24:0 SM | HMDB11697 | Phosphosphingolipids | −0.13, | 0.39 | −0.13, | −3% |
| Fumarate | HMDB00134 | Dicarboxylic acids/derivatives | 0.13, | 0.39 | 0.19, | −7% |
| C22:0 SM | HMDB12103 | Phosphosphingolipids | −0.13, | 0.39 | −0.15, | −10% |
| C20:5 LPC | HMDB10397 | Glycerophosphocholines | −0.12, | 0.39 | −0.06, | 40% |
| Salicylurate | HMDB00840 | Benzoic acids/derivatives | 0.12, | 0.41 | −0.02, | 118% |
| Homogentisate | HMDB00130 | Phenylacetic acids | 0.12, | 0.41 | 0.08, | 45% |
| Glycodeoxycholate | HMDB00631 | Bile acids, alcohols and derivatives | −0.12, | 0.42 | −0.13, | −13% |
| Malate | HMDB00156 | Beta hydroxy acids and derivatives | 0.12, | 0.42 | 0.16, | −9% |
| 5-hydroxytryptophan | HMDB00472 | Tryptamines and derivatives | −0.12, | 0.42 | −0.10, | 31% |
| C54:10 TAG | ---- | Triradylcglycerols | −0.12, | 0.43 | −0.16, | −23% |
| C44:13 PE plasmalogen | ---- | Glycerophosphoethanolamines | −0.12, | 0.44 | −0.07, | 23% |
1 Current smoking status, body mass index, appendicular lean mass, percent body fat, daily protein intake, interleukin-6, C-reactive protein, creatinine, cardiovascular disease, diabetes, pulmonary diseases, and total number of prescription medications. 2 Percent attenuation = 100*(r1−r2)/r1; where r1 = correlation coefficient between SAVE scores and a metabolite, adjusting for age and study site, r2 = correlation coefficient after further adjustments. Note: 30 participants were missing appendicular lean mass, percent body fat, daily protein intake, interleukin-6, C-reactive protein, and/or creatinine, thus, the correlation coefficient that was further adjusted for those variables was compared to the age- and study site-adjusted correlation coefficient restricted to the same sample size to calculate percent attenuation. Grey shading indicates metabolites that were significant (p < 0.05) after adjusting for multiple more commonly measured variables. SM = sphingomyelin. PE = phosphatidylethanolamine. CE = cholesteryl ester. LPC = lysophosphatidylcholine. TAG = triacylglycerol.
Figure 1Percent attenuations of the age- and study side- adjusted correlation between 37 metabolites (organized by Human Metabolome Database taxonomy super class) and scores on the Scale of Aging Vigor in Epidemiology (SAVE) after further adjusting for more commonly measured variables: (a) smoking status, (b) body mass index, (c) percent body fat and appendicular lean mass, (d) daily protein intake, (e) interleukin-6 and C-reactive protein, (f) creatinine, (g) prevalent diseases (cardiovascular diseases, diabetes, and pulmonary diseases), (h) medications (total number of prescription medications, anti-hypertensives, and medications for diabetes), or (i) multiple variables (smoking status, body mass index, appendicular lean mass, percent body fat, daily protein intake, interleukin-6, C-reactive protein, creatinine, cardiovascular disease, diabetes, pulmonary diseases, and total number of prescription medications).
Top results from a pathway analysis of 35 top metabolites 1 correlated with scores on the Scale of Aging Vigor in Epidemiology (SAVE; p < 0.05) among 287 black men from the Health, Aging, and Body Composition study.
| Pathways | Match Status | Fisher’s Exact Test | False Discovery Rate | Impact Score |
|---|---|---|---|---|
| Nitrogen metabolism | 5/39 | 0.00009 | 0.007 | 0.008 |
| Aminoacyl-tRNA biosynthesis | 6/75 | 0.0002 | 0.01 | 0 |
| Citric acid cycle | 3/20 | 0.002 | 0.05 | 0.12 |
| Tyrosine metabolism | 4/76 | 0.013 | 0.27 | 0.15 |
| Phenylalanine metabolism | 3/45 | 0.02 | 0.28 | 0 |
| Glycine, serine and threonine metabolism | 3/48 | 0.02 | 0.28 | 0 |
| Alanine, aspartate and glutamate metabolism | 2/24 | 0.03 | 0.37 | 0.05 |
| Sphingolipid metabolism | 2/25 | 0.04 | 0.37 | 0.30 |
| Phenylalanine, tyrosine and tryptophan biosynthesis | 2/27 | 0.04 | 0.37 | 0.007 |
| beta-Alanine metabolism | 2/28 | 0.05 | 0.37 | 0.04 |
1 The following 35 out of 37 metabolites that were correlated with SAVE scores at p < 0.05 had an identification number in the Human Metabolome Database and were included in the pathway analysis: glucuronate, tryptophan, methionine, N-carbamoyl-beta-alanine, tyrosine, isocitrate, creatinine, C4-OH carnitine, C14:0 SM, cystathionine, hydroxyphenylacetate, putrescine, 1-methylnicotinamide, asparagine, leucine, 5-aminolevulinic acid, inosine, histidine, C34:3 PE plasmalogen, SMDA, C24:1 ceramide (d18:1), C36:4 PE, urate, C18:2 CE, trimethylamine-N-oxide, 2-hydroxyglutarate, C24:0 SM, fumarate, C22:0 SM, C20:5 LPC, salicylurate, homogentisate, glycodeoxycholate/glycochenodeoxycholate, malate, and 5-hydroxytryptophan.
Tertile cut-offs of the five items used to calculate the Scale of Aging Vigor in Epidemiology (SAVE) for 287 black men from the Health, Aging, and Body Composition (Health ABC) study based on information from all Health ABC men.
| Five Items Used to Calculate the SAVE: | Best Tertile = 0 | Mid Tertile = 1 | Worst Tertile = 2 |
|---|---|---|---|
| 1. Weight change (kg) | >0.68 | <−1.36 to ≤0.68 | ≤−1.36 |
| 2. Physical activity 1 (kcal/kg/week) | ≥43 | >11 to <43 | ≤11 |
| 3. 20 m walk time (sec)** | ≤16 | >16 to ≤18 | >18 |
| 4. Grip strength (kg): | |||
| BMI < 24 | >38 | >32 to ≤38 | ≤32 |
| BMI ≥ 24 | >41 | >35 to ≤41 | ≤35 |
| 5. Usual energy level | 8 to 10 | 6 to 7 | 0 to 5 |
1 Total physical activity is based off of kcal/kg/week doing major chores, walking and climbing stairs, working, volunteering and caregiving (did not collect data for kcal/kg/week of exercise/recreation). 2 Tertiles for walk time did not differ for men by mean height.